Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more
Enlivex Therapeutics Ltd - Asset Resilience Ratio
Enlivex Therapeutics Ltd (ENLV) has an Asset Resilience Ratio of 67.44% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Enlivex Therapeutics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Enlivex Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $14.12 Million | 67.44% |
| Total Liquid Assets | $14.12 Million | 67.44% |
Asset Resilience Insights
- Very High Liquidity: Enlivex Therapeutics Ltd maintains exceptional liquid asset reserves at 67.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Enlivex Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Enlivex Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Enlivex Therapeutics Ltd (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Enlivex Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 72.94% | $20.20 Million | $27.69 Million | +0.97pp |
| 2023-12-31 | 71.97% | $26.51 Million | $36.83 Million | +71.53pp |
| 2022-12-31 | 0.44% | $299.00K | $67.64 Million | -76.21pp |
| 2021-12-31 | 76.65% | $72.93 Million | $95.15 Million | +2.23pp |
| 2020-12-31 | 74.42% | $30.03 Million | $40.36 Million | +28.52pp |
| 2019-12-31 | 45.90% | $8.06 Million | $17.56 Million | +45.54pp |
| 2018-12-31 | 0.36% | $40.00K | $11.03 Million | -27.93pp |
| 2016-12-31 | 28.29% | $3.01 Million | $10.63 Million | -30.43pp |
| 2015-12-31 | 58.72% | $12.05 Million | $20.52 Million | -8.13pp |
| 2014-12-31 | 66.84% | $22.03 Million | $32.95 Million | +66.11pp |
| 2007-12-31 | 0.74% | $311.00K | $42.20 Million | +0.33pp |
| 2006-12-31 | 0.41% | $113.00K | $27.69 Million | -5.52pp |
| 2005-12-31 | 5.92% | $2.67 Million | $45.14 Million | -0.05pp |
| 2004-12-31 | 5.98% | $2.71 Million | $45.27 Million | +3.88pp |
| 2003-12-31 | 2.09% | $958.00K | $45.74 Million | +0.43pp |
| 2002-12-31 | 1.67% | $890.00K | $53.35 Million | -9.75pp |
| 2001-12-31 | 11.42% | $7.07 Million | $61.92 Million | -3.93pp |
| 2000-12-31 | 15.34% | $15.71 Million | $102.40 Million | -- |